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It is often challenging to explain to potential transplant recipients that the mainstay of their 
immunosuppressive regimen is lifelong therapy with a calcineurin inhibitor (CNI). Despite careful 
monitoring of drug levels, these agents are nephrotoxic, reduce kidney transplant function, and for a 
small number of nonkidney transplant recipients, may even lead to kidney failure requiring dialysis 
or transplantation. Moreover, the available CNIs have a range of other side effects (hypertension, 
new-onset diabetes mellitus, dyslipidemia, neurotoxicity, and cosmetic effects) and may contribute 
to the increased risk for cardiovascular (CV) disease following transplantation. These factors may 
lead to nonadherence, which is a leading contributor to transplant failure, particularly in young 
people. As a consequence, we combine classes of immunosuppressive agents to minimize the side 
effect of each, and although CNI therapy has made solid-organ transplantation routine, the 
development of new agents that allow minimization of CNI or even CNI-free immunosuppression has 
become a priority.1 
 
In this issue of AJKD, Grinyo and colleagues2 provide further evidence that the costimulation blocker 
belatacept offers a viable alternative to CNI-based immunosuppression, raising the question as to 
why it has not been more widely adopted in kidney transplantation. Belatacept is given by injection 
every few weeks, circumventing adherence issues, and has no effect on the development of 
posttransplantation diabetes mellitus, dyslipidemia, or hypertension.3; 4;  5 The pivotal trials of de 
novo use, the Belatacept Evaluation of Nephroprotection and Efficacy as First-line 
Immunosuppression Trial (BENEFIT) and BENEFIT-Extended Criteria Donors (BENEFIT-EXT),3;  4 
demonstrated greatly improved kidney function at 1 year in recipients of standard and extended 
criteria donor kidneys.3;  4 Using mathematical modeling, we used the 1-year data to predict long-
term CV outcomes and survival over a 7-year horizon, predicting that the CV benefits of lower blood 
pressure, less dyslipidemia, and improved transplant function would be substantial, lead to 
improved survival, and as a consequence, be cost-effective despite the higher cost of treatment.5 
 
Although the early use of belatacept identified an increased risk for cerebral lymphoma, a severe 
challenge due to the limited treatment options, subsequent avoidance of belatacept treatment in 
patients with prior Epstein-Barr virus infection in both clinical trials and clinical use negated this 
safety concern. Follow-up of BENEFIT and BENEFIT-EXT to 7 years has confirmed the long-term 
safety and efficacy (specifically with respect to kidney function) of belatacept versus CNI-based 
therapy. In particular, the long-term follow-up of BENEFIT6 confirmed not only improved transplant 
function, but a substantial reduction in transplant loss and mortality, and despite the increased risk 
for acute rejection, there was no increase in the development of donor-specific antibodies. Overall, 
the longer term follow-up studies have confirmed the predicted outcomes based on 1-year 
outcomes5 and lend credence to the use of mathematical modeling strategies to predict long-
term outcomes in kidney transplantation studies. However, most importantly, they make an 
extremely strong case of the use of belatacept as primary immunosuppression. 
 
An alternative strategy is to start with CNI-based therapy (with which patients and clinicians are 
experienced and comfortable)7 and to switch at either a predefined time or in reaction to the 
development of CNI toxicity. In clinical practice, the former strategy is difficult to implement because 
neither the patient nor the physician is inclined to “rock the boat” when transplant function is 
stable. However, the reactive strategy, although more easily accepted, is often ineffective due to 
established pathology. Switch strategies have been extensively studied over the last decade, 
following the introduction of the mTOR (mammalian target of rapamycin) inhibitors sirolimus and 
everolimus. A series of studies investigated predetermined switches from CNI- to mTOR inhibitor–
based immunosuppression at time points from 7 days to many months after kidney transplantation, 
and others, the effect of later switches in patients with decreased kidney function.8; 9 The results can 
be summarized briefly as follows. In studies with follow-up of about 1 year, early switches are 
effective; the earlier the better. Switching to an mTOR inhibitor–based CNI-free regimen is typically 
associated with better transplant function and lower blood pressure at the expense of a slightly 
higher acute rejection rate, with persistent benefits reported at later time points in patients who 
remain on treatment. In contrast, reactive switches are not effective. In particular, patients with 
heavy proteinuria appear to have poor kidney outcomes, with increased proteinuria and accelerated 
transplant loss, although there may be some modest benefits in the subset of patients without 
proteinuria or with good transplant function.8; 9 However, the most important issue is tolerability. 
Side effects, including gastrointestinal symptoms, oral ulceration, skin rashes, dyslipidemia, and 
edema, limit mTOR inhibitor use in 30% to 50% of patients and have deterred clinicians from 
adopting these drugs more widely. Instead, their use is limited to patients intolerant of other agents 
or those with a past or current history of malignancy, particularly skin malignancy, for which the 
incidence and recurrence rates are reduced by mTOR inhibitors.10; 11 
 
In the current issue, Grinyo and colleagues report a study of a late switch from CNI-based 
immunosuppression to belatacept. The study population included 173 kidney transplant recipients 
with stable kidney function (mean estimated glomerular filtration rate, 53 mL/min/1.73 m2), half of 
whom were recipients of kidneys from live donors. Of these patients, 89 were randomly assigned to 
continue on CNI-based immunosuppression, and 84, to switch to belatacept 6 to 36 months after 
transplantation. Belatacept was started at a dose of 5 mg/kg given fortnightly, increasing to 4-
weekly by 2 months. The main trial reported outcomes at 24 months after transplantation, after 
which patients initially randomly assigned to CNI treatment were offered the opportunity to convert 
to belatacept (at the investigator’s discretion) in a long-term extension study. Sixteen patients 
switched to belatacept therapy. The analyses took into account the varying exposure to belatacept 
in the 2 groups with the primary aim of assessing long-term safety and efficacy. 
 
A total of 74 of 84 patients assigned initially to belatacept and 72 of 89 (including 16 who switched 
to belatacept after 2 years) assigned initially to CNI completed 36 months of follow-up. In the 
primary report, after 2 years of follow-up, patients randomly assigned to belatacept had improved 
transplant function.12 The current report confirms sustained improvement in kidney function 
despite the dilution of CNI exposure due to the inclusion of the 16 patients who converted. The 
study has other strengths. The CNI control arm included patients on tacrolimus and cyclosporine 
therapy, allowing comparison against the current standard therapy (rather than only cyclosporine), 
and there was a low incidence of donor-specific antibodies, in contrast to what is seen when 
switching to an mTOR inhibitor, further good news for long-term transplant function.13 
 
There are weaknesses. The small size and failure to include patients with poor or deteriorating 
kidney function or proteinuria means that the findings are not necessarily generalizable, specifically 
not to the setting in which CNI minimization or withdrawal is usually considered, although a recent 
report14 suggests similar benefits from belatacept conversion in kidney transplant recipients from 
extended criteria donors with poor transplant function (estimated glomerular filtration rate circa 
20 mL/min/1.73 m2). 
 
The new report from Grinyo et al is a confirmation of the 1- and 2-year follow-up of the original 
population described previously and needs to be viewed in that context. By itself, it is a rather small 
extension study that adds to available evidence on the tolerability and safety of prolonged use of 
belatacept. It confirms that belatacept-based CNI-free immunosuppression is associated with 
improved transplant function over 3 years with (unlike mTOR inhibitors) comparable safety and 
tolerability, as well as similar transplant and patient survival, to CNI. Like the mTOR inhibitor studies, 
switching was associated with an increased incidence of acute rejection, but without the expected 
effects on transplant function. This is likely to reflect the tendency to attribute increases in serum 
creatinine levels to the “experimental arm” of therapeutic trials, leading to a lower threshold for 
indication biopsies and thus more readily detecting low-grade rejection. However, it may reflect a 
change in the pathophysiology of acute rejection, uncoupling the established link between acute 
rejections and adverse transplant outcomes. Regardless, viewed in a broader context, the study is 
supportive of the strongly positive outcomes in the 7-year follow-up of de novo belatacept use in 
BENEFIT.6 Compared with other agents and late switch strategies, belatacept appears to be effective 
and well tolerated, with an improvement in kidney function likely to translate into long-term CV and 
mortality benefits.5 
 
To many, this study will appear to add to the body of evidence that belatacept should be the agent 
of choice in kidney transplantation and raises the question of its limited use. Although initially the 
risk for lymphoma deterred many and overall long-term outcome data are scarce compared with 
established agents, the hard truth is that the limits may be financial. Belatacept treatment is 
expensive and at least initially requires the infrastructure to administer outpatient infusions. Our 
modeling of its use suggested that prolonged transplant and patient survival, reduced monitoring, 
and lesser need for CV medications would reduce costs in the long term.5 The benefits to 
transplants and patients have been established, to which the present study contributes additional 
evidence; only the health economics of widespread use remains to be proved. However, the take 
home message in the current funding environment is that a switch from a CNI to belatacept in 
patients with reasonably preserved kidney function is safe, well tolerated, and associated with 
improved transplant function. 
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